The Medicines (MDCO) Hits New 1-Year Low at $27.32

The Medicines Company (NASDAQ:MDCO) shares reached a new 52-week low on Tuesday . The company traded as low as $27.32 and last traded at $28.34, with a volume of 841100 shares. The stock had previously closed at $28.50.

Several analysts recently issued reports on MDCO shares. Jefferies Group restated a “buy” rating and issued a $54.00 price target on shares of The Medicines in a research note on Thursday, October 26th. Guggenheim started coverage on The Medicines in a research note on Monday, October 23rd. They issued a “buy” rating and a $45.00 price target for the company. Chardan Capital restated a “buy” rating and issued a $85.00 price target on shares of The Medicines in a research note on Wednesday, September 20th. Zacks Investment Research upgraded The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Tuesday, August 8th. Finally, Cowen restated a “buy” rating and issued a $54.00 price target (down from $61.00) on shares of The Medicines in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $53.67.

The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42.

The Medicines (NASDAQ:MDCO) last released its earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.95. The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The company’s revenue was down 55.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.64) EPS. sell-side analysts anticipate that The Medicines Company will post -8.86 earnings per share for the current fiscal year.

In related news, Director Alexander J. Denner bought 170,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average cost of $30.03 per share, for a total transaction of $5,105,100.00. Following the transaction, the director now owns 6,663 shares in the company, valued at approximately $200,089.89. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 8.22% of the company’s stock.

Several large investors have recently added to or reduced their stakes in MDCO. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of The Medicines by 10.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after buying an additional 264 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of The Medicines during the 3rd quarter worth $171,000. First Mercantile Trust Co. raised its holdings in shares of The Medicines by 2.5% during the 2nd quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after buying an additional 114 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of The Medicines during the 3rd quarter worth $198,000. Finally, Bluefin Trading LLC acquired a new position in shares of The Medicines during the 2nd quarter worth $214,000.

WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/05/the-medicines-mdco-hits-new-1-year-low-at-27-32.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

What are top analysts saying about The Medicines Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit